Search 

A startup biotech focusing on novel therapeutic antibody discovery and development, particularly in fully human nanobody and bispecifics. Recently closed a Series A fund raising (USD $25M ).

苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台，其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体，酵母菌，和哺乳动物细胞展示平台。公司依托平台优势，在较短的时间内已经拥有十多个在研全新生物大分子药物，包括多个国际上首创的全人源纳米抗体（VH）和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.

Biotrak Capital is a healthcare-focused investment Fund with over 400M USD under management. In china but for global angle.

Shanghai based CRO and CDMO with offices in the US and Germany.

MNC

R&D attributed company

Founded in Wuxi, 2017
Focus on development, manufacturing and marketing of drugs
Registered capital is RMB 280M
Consists of Wuxi Fortune, Qingzhipin Pharma and Sihuan Pharma
Annual revenues - RMB 1 billion (~0.5 billion for antibiotics)
To be public company within 5 years in China

ophthalmic laser device R&D company

A pharmaceutical company

国家纳米科学院与广东